(19)
(11) EP 3 892 302 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.10.2023 Bulletin 2023/42

(45) Mention of the grant of the patent:
06.09.2023 Bulletin 2023/36

(21) Application number: 21161828.5

(22) Date of filing: 06.04.2016
(51) International Patent Classification (IPC): 
A61K 47/02(2006.01)
A61K 9/10(2006.01)
A61K 9/48(2006.01)
A61P 35/00(2006.01)
 A61K 47/12(2006.01)
A61K 47/38(2006.01)
A61K 31/519(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/02; A61K 47/12; A61K 9/10; A61K 47/38; A23L 33/10; A23L 33/16; A61K 31/519; A61K 9/4866; A61K 9/4858; A61K 9/4833; A61P 35/00; A61P 35/02; A61P 43/00

(54)

COMPOSITIONS CONTAINING IBRUTINIB

ZUSAMMENSETZUNGEN MIT IBRUTINIB

COMPOSITIONS CONTENANT DE L'IBRUTINIB

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 06.04.2015 US 201562143659 P

(43) Date of publication of application:
13.10.2021 Bulletin 2021/41

(60) Divisional application:
23194083.4

(62) Application number of the earlier application in accordance with Art. 76 EPC:
16718083.5 / 3280446

(73) Proprietor: Janssen Pharmaceutica NV
2340 Beerse (BE)

(72) Inventors:
  • GOLE, Dilip
    Raritan,, NJ New Jersey 08869 (US)
  • GUPTA, Manish Kumar
    400080 Mumbai Maharashtra (IN)
  • TAMBWEKAR, Kaustubh
    B-2340 Beerse (BE)
  • NAIR, Binuraj Krishnan
    400080 Mumbai Maharashtra (IN)
  • BERNINI, Maristella
    B-2340 Beerse (BE)
  • INGHELBRECHT, Sabine
    B-2340 Beerse (BE)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A1-2013/184572
US-A1- 2014 303 191
 WO-A1-2014/004707
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).